Source: Annual Congress 2010 - Influenza A (H1N1) and other viral infections: therapeutic aspects
Disease area: Respiratory infections

Abstract

Background: Frequent flashes of Severe acute respiratory syndrome and cases of infecting of people by the influenza-virus type A H5N1, H1N1 (California) came into a notice to viral pneumonia. Opening of human metapnevmovirus resulted in numerous researches, the purpose of which there was finding out of role of these viruses in the origin of respiratory tract infection.
Objectives: The purpose of our research was determination of spectrum of viral pathogens for patients with community-aquired pneumonia (CAP). Work was executed by the state budget financing.
Methods: For virologic research there was collected biomaterial from 301 patient with CAP. Selection and authentication of influenza-virus carried out with application of classic virologic methods of research. The exposures of antigens of influenza-virus carried by rapid diagnostic influenza AB tests, and method of indirect immunofluorescence. Serum diagnostics of influenza-virus was based on the exposure of increase of anti-influenza antibodies in 4 and more times, in the dynamics of disease, or on determination of specific class M (IGM) immunoproteins and carried out by classic serum methods of research.
Results: in 28,6% patients presence of viral etiopatogens: influenza-virus A – 15,6% patients, respiratory coronavirus – in 11,0%, adenovirus – in 1,3%, RS-virus – in 0,7%. In 18,6% from this patients were combination of viral and bacterial patogens. More frequent with bacterial pathogen were observed respiratory coronavirus (10,0% patients) and virus of influenza A. Most frequent co-pathogen there was S. pneumoniae. Most often viral co-pathogen was respiratory coronavirus (10%). However in most cases (54%) virus of influenza A observed as a monoinfection.

Rating:

Share or cite this content

Citations should be made in the following way:
O. Dziublyk, V. Kliagin (Kiev, Ukraine). Spectrum of viruses as a community-aquired pneumonia pathogens. Eur Respir J 2010; 36: Suppl. 54, 2987

Member's Comments

No comment yet.

Related content which might interest you: Prevalence of atypical bacterial pathogens in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The Netherlands Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Epidemiology of community-acquired pneumonia and nosocomial pneumonia Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 Risk factors for drug-resistant pathogens in patients with hospital-acquired and ventilator-associated pneumonia Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017 Multidrug-resistant bacteria in community-acquired pneumonia Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice Year: 2017 Multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia Source: Annual Congress 2013 –Recent developments in pneumonia Year: 2013 Bacterial infections and community-acquired pneumonia in children Source: Annual Congress 2011 - Paediatric Year in Review Year: 2011 The lung bacterial microbiome in community-acquired and nosocomial pneumonia Source: Eur Respir Monogr 2019; 83: 188-194 Year: 2019 Respiratory infections in the immunocompetent host: from asthma exacerbations to hospital-acquired pneumonia Source: Annual Congress 2007 - Infections year in review Year: 2007 Bacterial community-acquired pneumonia Source: Eur Respir Monogr 2014; 66: 98-111 Year: 2014 Drug-resistant pathogens prediction scores in CAP, HCAP and immunocompromised Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Carbapenem-resistant pathogens in US patients hospitalized with respiratory infections Source: International Congress 2018 – Clinical challenges in respiratory infection Year: 2018 Nosocomial superinfection is one of the principal cause of mortality in severe community-acquired pneumonia Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008 Spectrum of bacterial and viral pathogens of infectious exacerbation of COPD Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008 Ventilator-associated pneumonia: risk factors for antimicrobial-resistant causative pathogens Source: Eur Respir J 2006; 28: Suppl. 50, 785s Year: 2006 Nocardia community-acquired pneumonia in immunocompetent and immunocompromised host Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 Epidemiology, treatment and outcomes of nosocomial pneumonia due to Gram-negative bacteria Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007 The severity of Pneumocystis pneumonia without human immunodeficiency virus infection (non-HIV PCP) might be underestimated by conventional diagnostic rules for community-acquired pneumonia (CAP) Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 Impact of aspiration pneumonia in community-acquired pneumonia and healthcare-associated pneumonia Source: Annual Congress 2012 - CT findings: educational posters Year: 2012